New possibilities of neoadjuvant treatment of ER+ HER2- breast cancer in premenopausal patients
- Autores: Orlova R.V1,2, Vakhitova A.A1,2, Gluzman M.I1,2
-
Afiliações:
- City Clinical Oncological Dispensary
- Saint Petersburg State University
- Edição: Volume 28, Nº 7 (2021)
- Páginas: 56-60
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313179
- DOI: https://doi.org/10.18565/pharmateca.2021.7.56-60
- ID: 313179
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
While combined hormone therapy is the generally accepted standard regardless of the patient’s menopausal status in advanced ER+ HER2 breast cancer, in the case of neoadjuvant therapy for locally advanced forms, chemotherapy with the inclusion of anthracyclines and taxanes remains the standard. The objective of this review was the scientific substantiation of the advisability of using combined hormone therapy at the preoperative stage of treatment of this category of patients. After analyzing the information presented in electronic databases (PubMed, MEDLINE, BMS), as well as studying active clinical trials on the ClinicalTrials.gov portal, we concluded that most of the studies related to neoadjuvant hormone therapy were carried out on a population of postmenopausal patients. In this regard, a randomized controlled clinical trial to study the efficacy and safety of a new method of preoperative treatment in premenopausal women with ER+ HER2-locally advanced breast cancer was initiated.
Texto integral
Sobre autores
R. Orlova
City Clinical Oncological Dispensary; Saint Petersburg State UniversitySt. Petersburg, Russia
A. Vakhitova
City Clinical Oncological Dispensary; Saint Petersburg State University
Email: alberdovna@mail.ru
St. Petersburg, Russia
M. Gluzman
City Clinical Oncological Dispensary; Saint Petersburg State UniversitySt. Petersburg, Russia
Bibliografia
- DeVita V., Lawrence T., Rosenberg S., et al. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of oncology. 8th ed. Philadelphia: J.B. Lippincott, 2008. P. 1634.
- Каприн А.Д., Старинский В.В., Петрова Г. В. Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность), М., 2019.
- Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;2007(2):CD005002. doi: 10.1002/14651858.CD005002.pub2.
- Gianni L, Baselga J., Eiermann W., et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol. 2005;23(16_suppl):513.
- Rapoport B.L., Barnard-Tidy J., Van Eeden R.I. Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes. Ann Oncol. 2019;30(suppl_3). Doi: https://doi.org/10.W93/annonc/mdz097.012
- Zhou Q, Yin W., Du Y, Shen Z., Lu J. Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature. Menopause. 2015;22(10):1091-97. Doi: 10.W97/GME.0000000000000440.
- Matthew J. Elliscorresponding author and Cynthia Ma, Letrozole in the neoadjuvant setting: the P024 trial, Breast Cancer Res Treat. 2007; 105(Suppl 1):33-43. doi: 10.1007/s10549-007-9701-x.
- Kurosumi M., Takatsuka Y, Watanabe T. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial Randomized Controlled Trial. J Cancer Res Clin Oncol. 2008;134(6):715-22. doi: 10.1007/s00432-007-0343-5.
- Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. и др. Неоадъювантная терапия гормонозависимого рака молочной железы. Злокачественные опухоли. 2012;2(2):6-11.
- Torrisi R., Bagnardi V, Pruneri G. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802-8. doi: 10.1038/sj.bjc.6603947.
- Kim H.J., Noh W.C., tee E.S., et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res. 2020;22:54. Doi: 10.1186/ s13058-020-01288-5.
- Masuda N., Sagara Y, Kinoshita T. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial Clinical Trial. Lancet Oncol. 2012;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4.
- Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer, ClinicalTrials.gov Identifier: NCT03628066.
- URL: https://clinicaltrials.gov/ct2/show/ NCT04753177
Arquivos suplementares
